GSK Plays Down Seretide/Advair Generic Launch In U.K., But Pressure Builds
This article was originally published in The Pink Sheet Daily
Executive Summary
Mylan’s launch in the U.K. of the first generic version of anti-asthma drug Seretide (Advair in the U.S.) has been a long-time coming -- and the copycat version has key differences from the original -- but the event underscores building pressures on GSK’s respiratory franchise.